Abstract
Damage-associated molecular patterns (DAMPs) are critical mediators of immunogenic cell death (ICD), influencing the tumor immune microenvironment. This study introduces the DAMPscore, a 9-gene prognostic signature for hepatocellular carcinoma (HCC). Developed through machine learning and bioinformatics, the DAMPscore effectively stratifies patients by survival outcomes and immunotherapy response. Additionally, the study identifies TRIP13 as a key oncogenic hub gene that modulates sensitivity to chemotherapy-induced ICD.
Introduction
Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy with limited treatment options for advanced stages. The success of immunotherapy depends largely on the "immunogenicity" of the tumor. Immunogenic cell death (ICD) is a form of regulated cell death that triggers an adaptive immune response through the release of DAMPs. By quantifying DAMP-related gene expression, clinicians may better predict patient outcomes and tailor therapeutic strategies.
Methods
The researchers integrated multiple bioinformatics tools to construct the DAMPscore. Starting with 40 DAMP-related genes, consensus clustering identified distinct patient subgroups in the TCGA-LIHC training cohort. LASSO and stepwise regression narrowed this to a 9-gene signature: SLCO4C1, CD79A, PPARGC1A, GZMA, DAB2, VNN2, GHR, FSCN1, and LCAT. Validation was conducted using GSE14520 and ICGC-JP datasets. Immune profiling was performed using CIBERSORT and ESTIMATE algorithms. Weighted Correlation Network Analysis (WGCNA) identified TRIP13 as a hub gene, which was then validated through in vitro knockdown and overexpression experiments in HepG2 and LM3 cell lines.
Results
Stratification and Prognosis
The DAMPscore successfully classified HCC patients into high- and low-risk groups. Patients in the low DAMPscore group exhibited significantly longer overall survival. The model's predictive accuracy (AUC of 0.78 for 1-year survival) was superior to 53 other published mRNA signatures and standard clinical features.
Immune Microenvironment and Immunotherapy
Low DAMPscore tumors were associated with an "immune-hot" phenotype, characterized by high infiltration of CD8+ T cells and M1 macrophages. Analysis of external datasets confirmed that patients with low DAMPscores were more likely to respond to immunotherapy. In contrast, high DAMPscore patients showed potential sensitivity to targeted inhibitors of the PI3K and p38α pathways.
TRIP13 as a Therapeutic Target
TRIP13 (Thyroid hormone receptor interactor 13) emerged as a critical driver of the DAMPscore. In vitro assays showed that TRIP13 promotes HCC cell proliferation and migration. Silencing TRIP13 increased the expression of the pro-apoptotic protein Bax while decreasing the anti-apoptotic protein Bcl-2. Crucially, TRIP13 knockdown sensitized HCC cells to 5-Fluorouracil (5-FU), suggesting that targeting this gene could enhance the effects of ICD-inducing chemotherapy.
Conclusion
The DAMPscore is a robust tool for predicting prognosis and treatment response in HCC. By identifying TRIP13 as a key regulator of chemoresistance and tumor progression, this study provides a dual-purpose biomarker for both prognostic stratification and therapeutic targeting. Future prospective trials are necessary to validate these findings in clinical practice.
Summary updated